Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway

Asthenozoospermia Clinical Trial

Official title:

Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01684059
• Other study ID #: Babil-2
• Status: Completed
• Phase: N/A
• First received: September 9, 2012
• Last updated: September 11, 2012
• Start date: July 2011
• Est. completion date: July 2012

Study information

• Verified date: September 2012
• Source: Babylon University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iraq: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The ability of spermatozoa to produce reactive oxygen species (ROS) has been respected since the 1940's. Oxidative stress limits the functional competence of mammalian spermatozoa via lipid peroxidation, the induction of oxidative DNA damage and the formation of protein adducts. Nitric oxide (NO) is a free radical generated from the oxidation of L-arginine to L-citrulline by reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent NO synthases. Several studies suggest that the overproduction of this free radical and the subsequent excessive exposure to oxidative conditions have a potential pathogenetic implication, which due to the reduction of sperm motility. The present study was conducted to study the effect of Zn supplementation on the levels of NO synthase and arginase in semen of patients with asthenozoospmia.

Description:

Previous studies suggest that high concentrations of NO play an injurious consequence on spermatozoa kinetic characteristics. These studies reported that NO may react with superoxide or hydrogen peroxide, resulting in the production of peroxinitrite, hydroxyl radical, or singlet oxygen, which cause oxidation of sperm membrane lipids and thiol proteins. NO also may inhibit cellular respiration by nitro-sylation of heme in mitochondrial enzymes, aconitase, and glyceraldehyde phosphate dehydrogenase, leading to a reduction of adenosine triphosphate and that is due to loss of motility of spermatozoa.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 27 Years to 35 Years

Eligibility

Inclusion Criteria:

• the presence of asthenozoospermia in the semen sample.

Exclusion Criteria:

• the absence of endocrinopathy,

• varicocele, and

• female factor infertility. Smokers and alcoholic men were excluded from the study because of their recognized high seminal ROS levels and decreased antioxidant levels

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Asthenozoospermia

Intervention

Dietary Supplement:
• zinc sulfate
every participant took two capsules of zinc sulfate per day for three months (each one 220mg)

Locations

Country	Name	City	State
Iraq	Babylon university/ college of science	Hilla

Sponsors (2)

Lead Sponsor	Collaborator
Babylon University	Ministry of health/Iraq

Country where clinical trial is conducted

Iraq, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nitric oxide synthase activity		at the end of three months	Yes
Secondary	Arginase activity		at the end of three months	Yes